中文

Hong Kong Stocks · Free Data Page

INNOVENT BIO 01801

INNOVENT BIO: FY2025 revenue CN¥13.04B (+38.40% YoY); net income CN¥813.6M; 0 alerts, 1 watch item out of 17 risk checks; no TTM dividend.
Close PriceHK$85.05Day +7.18%Market CapHK$148.6BP/E104.0xTTMP/B6.22xROE (FY2025)5.0%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for INNOVENT BIO?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023, FY2024.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)4.274.566.219.4213.0
YoY11.1%6.7%36.2%51.8%38.4%
Net Income (CNY B)-2.73-2.18-1.03-0.090.81
Operating Cash Flow (CNY B)-2.02-1.920.151.2910.0
ROE-28.6%-20.7%-8.8%-0.7%5.0%
Gross Margin88.2%79.6%81.7%84.0%86.5%
Net Margin-63.9%-47.8%-16.6%-1.0%6.2%
Debt-to-Assets36.4%39.0%39.3%39.3%48.2%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)—0.020.011.053.844.274.566.219.4213.0
YoY——-48.9%10953.3%266.9%11.1%6.7%36.2%51.8%38.4%
Net Income (CNY B)-0.50-0.56-5.77-1.72-1.00-2.73-2.18-1.03-0.090.81
Operating Cash Flow (CNY B)-0.36-0.49-1.01-1.66-0.31-2.02-1.920.151.2910.0
ROE——-137.6%—-11.4%-28.6%-20.7%-8.8%-0.7%5.0%
Gross Margin—100.0%100.0%88.1%89.9%88.2%79.6%81.7%84.0%86.5%
Net Margin—-3033.3%-60900.0%-164.2%-26.0%-63.9%-47.8%-16.6%-1.0%6.2%
Debt-to-Assets134.0%166.0%31.4%—25.8%36.4%39.0%39.3%39.3%48.2%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 1Watch 15Pass 1N/A

Items Flagged for Review

  • Watch

    Inventory DaysFinancial Quality

    270.6 days, prior FY 198.7 days(+36%)

    FY2025 (ended 2025-12-31) · What is this?

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

No dividends paid over the trailing 12 months.

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.